View More

Peter Nowell and David Hungerford in 1960

 

Chronic Myeloid Leukemia (CML) is not a cancer you hear about very often. That’s not because it isn’t serious β€” until recently, it carried a frightening prognoses. Until about 2000, newly diagnosed CML patients had a 5-year survival rate of 31%. But we don’t hear much about CML because it is a rare disease, and affects far fewer people than cancers of the breast or prostate, or lung cancer.Read the rest “Chronic Myeloid Leukemia: a Molecular Diagnosis”

View More

Dr. Brian Druker and Ms. LaDonna Lopossa, one of the earliest patients to benefit from Gleevec

Rob Schick is the Branch Manger of the Baird Wealth Management Group in Portland, Oregon. Most people would probably consider him lucky. For starters, Portland is one of the most desirable cities in the United States to live in. He and his wife have three grown children, one of whom works at the same company. In addition to his success in business, Rob Schick’s efforts on behalf of the Knight Cancer Institute, where he has helped raise millions of dollars for research, were nationally recognized in 2015 by a National Community Service Award from the Invest in Others Foundation.Read the rest “Chronic Myeloid Leukemia: A Molecular Solution”

View More

If there were a contest to name the most-hated chemical, Roundup, Monsanto’s brand name for the chemical Glyphosate, would have a very good chance of winning. It has been identified not only as a plant poison, but also a destroyer of monarch butterflies, an impoverisher of developing-world farmers, and a probable carcinogen. These are serious issues. But they are also complex, and I will argue, they are not settled (except for being a plant poison).Read the rest “The Trouble With Roundup”